Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 17 entries
Sorted by: Best Match Show Resources per page
Spindle cell carcinoma of the head and neck region: treatment and outcomes of 15 patients.

Ecancermedicalscience

Iqbal MS, Paleri V, Brown J, Greystoke A, Dobrowsky W, Kelly C, Kovarik J.
PMID: 26635898
Ecancermedicalscience. 2015 Nov 18;9:594. doi: 10.3332/ecancer.2015.594. eCollection 2015.

INTRODUCTION: Spindle cell carcinoma of the head and neck is a rare entity and the evidence of optimal management is lacking. The objective of our study was to report the treatment and outcomes of 15 patients treated in a...

Cite
Iqbal MS, Paleri V, Brown J, et al. Spindle cell carcinoma of the head and neck region: treatment and outcomes of 15 patients. Ecancermedicalscience. 2015;9:594doi: 10.3332/ecancer.2015.594.
Iqbal, M. S., Paleri, V., Brown, J., Greystoke, A., Dobrowsky, W., Kelly, C., & Kovarik, J. (2015). Spindle cell carcinoma of the head and neck region: treatment and outcomes of 15 patients. Ecancermedicalscience, 9594. https://doi.org/10.3332/ecancer.2015.594
Iqbal, Muhammad Shahid, et al. "Spindle cell carcinoma of the head and neck region: treatment and outcomes of 15 patients." Ecancermedicalscience vol. 9 (2015): 594. doi: https://doi.org/10.3332/ecancer.2015.594
Iqbal MS, Paleri V, Brown J, Greystoke A, Dobrowsky W, Kelly C, Kovarik J. Spindle cell carcinoma of the head and neck region: treatment and outcomes of 15 patients. Ecancermedicalscience. 2015 Nov 18;9:594. doi: 10.3332/ecancer.2015.594. eCollection 2015. PMID: 26635898; PMCID: PMC4659701.
Copy Download .nbib Format: NLM
Lactic acidosis expediting a diagnosis of acute lymphoblastic leukaemia.

BMJ case reports

Young H, Singh S, Greystoke BF, Willert RP.
PMID: 21747899
BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.02.2009.1601. Epub 2009 Jul 12.

We report the finding of a low venous bicarbonate and lactic acidosis in a patient with mild pancytopenia which raised the suspicion of haematological malignancy and expedited the diagnosis of acute lymphoblastic leukaemia. This report highlights the value of...

Cite
Young H, Singh S, Greystoke BF, et al. Lactic acidosis expediting a diagnosis of acute lymphoblastic leukaemia. BMJ Case Rep. 2009;2009doi: 10.1136/bcr.02.2009.1601.
Young, H., Singh, S., Greystoke, B. F., & Willert, R. P. (2009). Lactic acidosis expediting a diagnosis of acute lymphoblastic leukaemia. BMJ case reports, 2009. https://doi.org/10.1136/bcr.02.2009.1601
Young, Heather, et al. "Lactic acidosis expediting a diagnosis of acute lymphoblastic leukaemia." BMJ case reports vol. 2009 (2009). doi: https://doi.org/10.1136/bcr.02.2009.1601
Young H, Singh S, Greystoke BF, Willert RP. Lactic acidosis expediting a diagnosis of acute lymphoblastic leukaemia. BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.02.2009.1601. Epub 2009 Jul 12. PMID: 21747899; PMCID: PMC3028298.
Copy Download .nbib Format: NLM
Metastatic Brain Disease from Non-small Cell Lung Cancer - Getting Back to the Drawing Board.

Clinical oncology (Royal College of Radiologists (Great Britain))

Greystoke A, Mulvenna P.
PMID: 29352644
Clin Oncol (R Coll Radiol). 2018 Mar;30(3):137-143. doi: 10.1016/j.clon.2017.12.020. Epub 2018 Jan 17.

No abstract available.

Cite
Greystoke A, Mulvenna P. Metastatic Brain Disease from Non-small Cell Lung Cancer - Getting Back to the Drawing Board. Clin Oncol (R Coll Radiol). 2018;30(3):137-143doi: 10.1016/j.clon.2017.12.020.
Greystoke, A., & Mulvenna, P. (2018). Metastatic Brain Disease from Non-small Cell Lung Cancer - Getting Back to the Drawing Board. Clinical oncology (Royal College of Radiologists (Great Britain)), 30(3), 137-143. https://doi.org/10.1016/j.clon.2017.12.020
Greystoke, A, and Mulvenna, P. "Metastatic Brain Disease from Non-small Cell Lung Cancer - Getting Back to the Drawing Board." Clinical oncology (Royal College of Radiologists (Great Britain)) vol. 30,3 (2018): 137-143. doi: https://doi.org/10.1016/j.clon.2017.12.020
Greystoke A, Mulvenna P. Metastatic Brain Disease from Non-small Cell Lung Cancer - Getting Back to the Drawing Board. Clin Oncol (R Coll Radiol). 2018 Mar;30(3):137-143. doi: 10.1016/j.clon.2017.12.020. Epub 2018 Jan 17. PMID: 29352644.
Copy Download .nbib Format: NLM
[A Rare Case of Non-small Cell Lung Carcinoma Squamous Phenotype with Epstein-Barr Virus Positivity with Prolonged Response to both Chemotherapy and Radiotherapy].

Zhongguo fei ai za zhi = Chinese journal of lung cancer

Rodriguez CN, Iqbal MS, Robinson M, Burns G, Greystoke A.
PMID: 34275518
Zhongguo Fei Ai Za Zhi. 2021 Jul 20;24(7):526-528. doi: 10.3779/j.issn.1009-3419.2021.101.15.

We present a rare challenging case of metastatic non-small cell lung cancer with Epstein-Barr virus positivity that was also diagnosed with pulmonary tuberculosis at the same time. Palliative chemotherapy gemcitabine and carboplatin was started after two weeks of anti-tuberculosis...

Cite
Rodriguez CN, Iqbal MS, Robinson M, et al. [A Rare Case of Non-small Cell Lung Carcinoma Squamous Phenotype with Epstein-Barr Virus Positivity with Prolonged Response to both Chemotherapy and Radiotherapy]. Zhongguo Fei Ai Za Zhi. 2021;24(7):526-528doi: 10.3779/j.issn.1009-3419.2021.101.15.
Rodriguez, C. N., Iqbal, M. S., Robinson, M., Burns, G., & Greystoke, A. (2021). [A Rare Case of Non-small Cell Lung Carcinoma Squamous Phenotype with Epstein-Barr Virus Positivity with Prolonged Response to both Chemotherapy and Radiotherapy]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 24(7), 526-528. https://doi.org/10.3779/j.issn.1009-3419.2021.101.15
Rodriguez, Carolina Navarro, et al. "[A Rare Case of Non-small Cell Lung Carcinoma Squamous Phenotype with Epstein-Barr Virus Positivity with Prolonged Response to both Chemotherapy and Radiotherapy]." Zhongguo fei ai za zhi = Chinese journal of lung cancer vol. 24,7 (2021): 526-528. doi: https://doi.org/10.3779/j.issn.1009-3419.2021.101.15
Rodriguez CN, Iqbal MS, Robinson M, Burns G, Greystoke A. [A Rare Case of Non-small Cell Lung Carcinoma Squamous Phenotype with Epstein-Barr Virus Positivity with Prolonged Response to both Chemotherapy and Radiotherapy]. Zhongguo Fei Ai Za Zhi. 2021 Jul 20;24(7):526-528. doi: 10.3779/j.issn.1009-3419.2021.101.15. Chinese. PMID: 34275518; PMCID: PMC8317097.
Copy Download .nbib Format: NLM
The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform.

Clinical oncology (Royal College of Radiologists (Great Britain))

Faivre-Finn C, Brown S, Ryan A, Greystoke A.
PMID: 32107107
Clin Oncol (R Coll Radiol). 2020 Jun;32(6):358-362. doi: 10.1016/j.clon.2020.02.003. Epub 2020 Feb 24.

No abstract available.

Cite
Faivre-Finn C, Brown S, Ryan A, et al. The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform. Clin Oncol (R Coll Radiol). 2020;32(6):358-362doi: 10.1016/j.clon.2020.02.003.
Faivre-Finn, C., Brown, S., Ryan, A., Greystoke, A. (2020). The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform. Clinical oncology (Royal College of Radiologists (Great Britain)), 32(6), 358-362. https://doi.org/10.1016/j.clon.2020.02.003
Faivre-Finn, C, et al. "The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform." Clinical oncology (Royal College of Radiologists (Great Britain)) vol. 32,6 (2020): 358-362. doi: https://doi.org/10.1016/j.clon.2020.02.003
Faivre-Finn C, Brown S, Ryan A, Greystoke A. The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform. Clin Oncol (R Coll Radiol). 2020 Jun;32(6):358-362. doi: 10.1016/j.clon.2020.02.003. Epub 2020 Feb 24. PMID: 32107107.
Copy Download .nbib Format: NLM
A feasibility study to investigate the utility of a home-based exercise intervention during and after neo-adjuvant chemotherapy for oesophago-gastric cancer-the ChemoFit study protocol.

Pilot and feasibility studies

Chmelo J, Phillips AW, Greystoke A, Charman SJ, Avery L, Hallsworth K, Welford J, Sinclair RCF.
PMID: 32346484
Pilot Feasibility Stud. 2020 Apr 23;6:50. doi: 10.1186/s40814-020-00597-y. eCollection 2020.

BACKGROUND: Treatment of locally advanced oesophago-gastric adenocarcinoma usually entails neo-adjuvant chemotherapy (NAC) and surgery. Surgery is associated with high morbidity and mortality. Cardiopulmonary reserve of patients having major surgery is related to postoperative outcomes. Complications are associated with poorer...

Cite
Chmelo J, Phillips AW, Greystoke A, et al. A feasibility study to investigate the utility of a home-based exercise intervention during and after neo-adjuvant chemotherapy for oesophago-gastric cancer-the ChemoFit study protocol. Pilot Feasibility Stud. 2020;6:50doi: 10.1186/s40814-020-00597-y.
Chmelo, J., Phillips, A. W., Greystoke, A., Charman, S. J., Avery, L., Hallsworth, K., Welford, J., & Sinclair, R. C. F. (2020). A feasibility study to investigate the utility of a home-based exercise intervention during and after neo-adjuvant chemotherapy for oesophago-gastric cancer-the ChemoFit study protocol. Pilot and feasibility studies, 650. https://doi.org/10.1186/s40814-020-00597-y
Chmelo, J, et al. "A feasibility study to investigate the utility of a home-based exercise intervention during and after neo-adjuvant chemotherapy for oesophago-gastric cancer-the ChemoFit study protocol." Pilot and feasibility studies vol. 6 (2020): 50. doi: https://doi.org/10.1186/s40814-020-00597-y
Chmelo J, Phillips AW, Greystoke A, Charman SJ, Avery L, Hallsworth K, Welford J, Sinclair RCF. A feasibility study to investigate the utility of a home-based exercise intervention during and after neo-adjuvant chemotherapy for oesophago-gastric cancer-the ChemoFit study protocol. Pilot Feasibility Stud. 2020 Apr 23;6:50. doi: 10.1186/s40814-020-00597-y. eCollection 2020. PMID: 32346484; PMCID: PMC7181593.
Copy Download .nbib Format: NLM
Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer.

Nature

Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, Yap TA, Watkins TBK, Lim E, Swanton C, Billingham L.
PMID: 32887973
Nature. 2020 Sep;585(7826):E21. doi: 10.1038/s41586-020-2656-3.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cite
Middleton G, Fletcher P, Popat S, et al. Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. 2020;585(7826):E21doi: 10.1038/s41586-020-2656-3.
Middleton, G., Fletcher, P., Popat, S., Savage, J., Summers, Y., Greystoke, A., Gilligan, D., Cave, J., O'Rourke, N., Brewster, A., Toy, E., Spicer, J., Jain, P., Dangoor, A., Mackean, M., Forster, M., Farley, A., Wherton, D., Mehmi, M., Sharpe, R., Mills, T. C., Cerone, M. A., Yap, T. A., Watkins, T. B. K., Lim, E., Swanton, C., & Billingham, L. (2020). Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer. Nature, 585(7826), E21. https://doi.org/10.1038/s41586-020-2656-3
Middleton, Gary, et al. "Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer." Nature vol. 585,7826 (2020): E21. doi: https://doi.org/10.1038/s41586-020-2656-3
Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, Yap TA, Watkins TBK, Lim E, Swanton C, Billingham L. Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. 2020 Sep;585(7826):E21. doi: 10.1038/s41586-020-2656-3. PMID: 32887973.
Copy Download .nbib Format: NLM
How many diseases are colorectal cancer?.

Gastroenterology research and practice

Greystoke A, Mullamitha SA.
PMID: 22991509
Gastroenterol Res Pract. 2012;2012:564741. doi: 10.1155/2012/564741. Epub 2012 Sep 09.

The development of personalised therapy and mechanism-targeted agents in oncology mandates the identification of the patient populations most likely to benefit from therapy. This paper discusses the increasing evidence as to the heterogeneity of the group of diseases called...

Cite
Greystoke A, Mullamitha SA. How many diseases are colorectal cancer?. Gastroenterol Res Pract. 2012;2012:564741doi: 10.1155/2012/564741.
Greystoke, A., & Mullamitha, S. A. (2012). How many diseases are colorectal cancer?. Gastroenterology research and practice, 2012564741. https://doi.org/10.1155/2012/564741
Greystoke, A, and Mullamitha, S A. "How many diseases are colorectal cancer?." Gastroenterology research and practice vol. 2012 (2012): 564741. doi: https://doi.org/10.1155/2012/564741
Greystoke A, Mullamitha SA. How many diseases are colorectal cancer?. Gastroenterol Res Pract. 2012;2012:564741. doi: 10.1155/2012/564741. Epub 2012 Sep 09. PMID: 22991509; PMCID: PMC3444041.
Copy Download .nbib Format: NLM
Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.

British journal of cancer

McNeillis R, Greystoke A, Walton J, Bacon C, Keun H, Siskos A, Petrides G, Leech N, Jenkinson F, Bowron A, Halford S, Plummer R.
PMID: 32203218
Br J Cancer. 2020 Apr;122(8):1272. doi: 10.1038/s41416-020-0801-2.

Since the publication of this paper the authors noticed an error in the listed authors, where Alexandros Siskos was listed as Alexandros Sitkos. This has now been corrected.

Cite
McNeillis R, Greystoke A, Walton J, et al. Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965. Br J Cancer. 2020;122(8):1272doi: 10.1038/s41416-020-0801-2.
McNeillis, R., Greystoke, A., Walton, J., Bacon, C., Keun, H., Siskos, A., Petrides, G., Leech, N., Jenkinson, F., Bowron, A., Halford, S., & Plummer, R. (2020). Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965. British journal of cancer, 122(8), 1272. https://doi.org/10.1038/s41416-020-0801-2
McNeillis, Rosie, et al. "Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965." British journal of cancer vol. 122,8 (2020): 1272. doi: https://doi.org/10.1038/s41416-020-0801-2
McNeillis R, Greystoke A, Walton J, Bacon C, Keun H, Siskos A, Petrides G, Leech N, Jenkinson F, Bowron A, Halford S, Plummer R. Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965. Br J Cancer. 2020 Apr;122(8):1272. doi: 10.1038/s41416-020-0801-2. PMID: 32203218; PMCID: PMC7156454.
Copy Download .nbib Format: NLM
Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer.

British journal of cancer

Harvie M, Pegington M, Howell SJ, Bundred N, Foden P, Adams J, Graves L, Greystoke A, Mattson MP, Cutler RG, Williamson J, Livingstone K, McMullen D, Sellers K, Lombardelli C, Cooper G, McDiarmid S, Howell A.
PMID: 34912072
Br J Cancer. 2021 Dec 15; doi: 10.1038/s41416-021-01650-0. Epub 2021 Dec 15.

BACKGROUND: Excess adiposity at diagnosis and weight gain during chemotherapy is associated with tumour recurrence and chemotherapy toxicity. We assessed the efficacy of intermittent energy restriction (IER) vs continuous energy restriction (CER) for weight control and toxicity reduction during...

Cite
Harvie M, Pegington M, Howell SJ, et al. Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. Br J Cancer. 2021;doi: 10.1038/s41416-021-01650-0.
Harvie, M., Pegington, M., Howell, S. J., Bundred, N., Foden, P., Adams, J., Graves, L., Greystoke, A., Mattson, M. P., Cutler, R. G., Williamson, J., Livingstone, K., McMullen, D., Sellers, K., Lombardelli, C., Cooper, G., McDiarmid, S., & Howell, A. (2021). Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. British journal of cancer, . https://doi.org/10.1038/s41416-021-01650-0
Harvie, Michelle, et al. "Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer." British journal of cancer vol. (2021). doi: https://doi.org/10.1038/s41416-021-01650-0
Harvie M, Pegington M, Howell SJ, Bundred N, Foden P, Adams J, Graves L, Greystoke A, Mattson MP, Cutler RG, Williamson J, Livingstone K, McMullen D, Sellers K, Lombardelli C, Cooper G, McDiarmid S, Howell A. Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. Br J Cancer. 2021 Dec 15; doi: 10.1038/s41416-021-01650-0. Epub 2021 Dec 15. PMID: 34912072.
Copy Download .nbib Format: NLM
Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective.

PharmacoEconomics - open

Dunlop W, van Keep M, Elroy P, Perez ID, Ouwens MJNM, Sarbajna T, Zhang Y, Greystoke A.
PMID: 34532842
Pharmacoecon Open. 2021 Sep 16; doi: 10.1007/s41669-021-00301-7. Epub 2021 Sep 16.

BACKGROUND: In the phase III PACIFIC study, durvalumab improved survival versus placebo in patients with unresectable stage III non-small-cell lung cancer (NSCLC) whose disease had not progressed after platinum-based concurrent chemoradiotherapy. The appraisal by the UK's National Institute for...

Cite
Dunlop W, van Keep M, Elroy P, et al. Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective. Pharmacoecon Open. 2021;doi: 10.1007/s41669-021-00301-7.
Dunlop, W., van Keep, M., Elroy, P., Perez, I. D., Ouwens, M. J. N. M., Sarbajna, T., Zhang, Y., & Greystoke, A. (2021). Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective. PharmacoEconomics - open, . https://doi.org/10.1007/s41669-021-00301-7
Dunlop, Will, et al. "Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective." PharmacoEconomics - open vol. (2021). doi: https://doi.org/10.1007/s41669-021-00301-7
Dunlop W, van Keep M, Elroy P, Perez ID, Ouwens MJNM, Sarbajna T, Zhang Y, Greystoke A. Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective. Pharmacoecon Open. 2021 Sep 16; doi: 10.1007/s41669-021-00301-7. Epub 2021 Sep 16. PMID: 34532842.
Copy Download .nbib Format: NLM
The care of older cancer patients in the United Kingdom.

Ecancermedicalscience

Gomes F, Lewis A, Morris R, Parks R, Kalsi T, Babic-Illamn G, Baxter M, Colquhoun K, Rodgers L, Smith E, Greystoke A, Bayman N, Cree A, Ng C, de Liguori Carino N, Basile S, Moore J, Merchant Z, Swinson D, Parbhoo A, Jones R, Davies E, Danson SJ, Young R, Morgan J, Wyld L, Corrie PG, Doherty GJ, Crawford K, Wright J, Reed M, Ugolini F, Lind M, Cheung KL, Harari D, Simcock R.
PMID: 33082851
Ecancermedicalscience. 2020 Sep 15;14:1101. doi: 10.3332/ecancer.2020.1101. eCollection 2020.

The ageing population poses new challenges globally. Cancer care for older patients is one of these challenges, and it has a significant impact on societies. In the United Kingdom (UK), as the number of older cancer patients increases, the...

Cite
Gomes F, Lewis A, Morris R, et al. The care of older cancer patients in the United Kingdom. Ecancermedicalscience. 2020;14:1101doi: 10.3332/ecancer.2020.1101.
Gomes, F., Lewis, A., Morris, R., Parks, R., Kalsi, T., Babic-Illamn, G., Baxter, M., Colquhoun, K., Rodgers, L., Smith, E., Greystoke, A., Bayman, N., Cree, A., Ng, C., de Liguori Carino, N., Basile, S., Moore, J., Merchant, Z., Swinson, D., Parbhoo, A., Jones, R., Davies, E., Danson, S. J., Young, R., Morgan, J., Wyld, L., Corrie, P. G., Doherty, G. J., Crawford, K., Wright, J., Reed, M., Ugolini, F., Lind, M., Cheung, K. L., Harari, D., & Simcock, R. (2020). The care of older cancer patients in the United Kingdom. Ecancermedicalscience, 141101. https://doi.org/10.3332/ecancer.2020.1101
Gomes, Fabio, et al. "The care of older cancer patients in the United Kingdom." Ecancermedicalscience vol. 14 (2020): 1101. doi: https://doi.org/10.3332/ecancer.2020.1101
Gomes F, Lewis A, Morris R, Parks R, Kalsi T, Babic-Illamn G, Baxter M, Colquhoun K, Rodgers L, Smith E, Greystoke A, Bayman N, Cree A, Ng C, de Liguori Carino N, Basile S, Moore J, Merchant Z, Swinson D, Parbhoo A, Jones R, Davies E, Danson SJ, Young R, Morgan J, Wyld L, Corrie PG, Doherty GJ, Crawford K, Wright J, Reed M, Ugolini F, Lind M, Cheung KL, Harari D, Simcock R. The care of older cancer patients in the United Kingdom. Ecancermedicalscience. 2020 Sep 15;14:1101. doi: 10.3332/ecancer.2020.1101. eCollection 2020. PMID: 33082851; PMCID: PMC7532033.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 17 entries